International Journal of Heart Failure · Oct 6, 2026

Clonal Hematopoiesis of Indeterminate Potential and Heart Failure: Mechanisms, Risk Stratification, and Therapeutic Implications

By Park JB

Clonal hematopoiesis of indeterminate potential (CHIP) is an age-related expansion of hematopoietic clones carrying somatic driver variants and has been consistently associated with cardiovascular disease. Observational studies associate CHIP with incident heart failure (HF) and adverse outcomes, with substantial heterogeneity according to driver gene and clone size. The most coherent phenotype-specific evidence involves older, inflammation-enriched populations and HF with preserved ejection fraction, particularly TET2-related CHIP; evidence in HF with reduced ejection fraction, ischemic HF, and non-ischemic cardiomyopathy is less mature and largely prognostic. Gene-specific experimental models show that TET2 loss can amplify interleukin-1β/NOD-, LRR- and pyrin domain-containing protein 3 signaling, DNMT3A-mutant hematopoiesis can promote fibroblast activation, and JAK2V617F can enhance thrombo-inflammation. These findings provide biological plausibility but do not establish CHIP as a causal driver of HF in humans. Any future clinical translation will require standardized sequencing and variant interpretation, validated variant allele frequency thresholds, demonstration of incremental prognostic utility and cost-effectiveness, and evidence that CHIP-guided management improves clinical outcomes. No CHIP-directed HF therapy or routine testing strategy is currently recommended. Exploratory genomic analyses of CANTOS and ongoing inflammation-enriched trials provide opportunities to evaluate CHIP as a prognostic, trial-enrichment, or predictive biomarker. This review synthesizes current epidemiologic and mechanistic evidence, highlights phenotype-specific limitations, and outlines priorities for prospective validation.

doi.org/10.36628/ijhf.2026.0072Open accessPubMed 43010965Mechanisms

AgingResearch.News